Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17053389 | 0.90 | PIK3CD (0.49) | PIK3CDPIK3CA | |
| SCHEMBL16639139 | 0.84 | PIK3CA (0.62) | PIK3CDPIK3CAMTORPIK3CG | |
| SCHEMBL20725675 | 0.82 | PIK3CD (0.66) | PIK3CDPIK3CA | |
| SCHEMBL17946353 | 0.82 | PIK3CD (0.72) | PIK3CDPIK3CA | |
| SCHEMBL16639103 | 0.82 | PIK3CA (0.64) | PIK3CDPIK3CAPIK3CBMTORPIK3CG | |
| SCHEMBL16639134 | 0.81 | PIK3CD (0.42) | PIK3CDPIK3CAMTOR | |
| SCHEMBL17053417 | 0.80 | PIK3CD (0.58) | PIK3CDPIK3CA | |
| SCHEMBL16639117 | 0.79 | PIK3CD (0.51) | PIK3CDPIK3CAMTORPIK3CG | |
| SCHEMBL16639067 | 0.79 | PIK3CD (0.80) | PIK3CDPIK3CA | |
| SCHEMBL17053388 | 0.79 | CYP2A6 (0.45) | PIK3CDPIK3CAPIK3CBMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860181-B1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| EP-2860181-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | Shanghai Yingli Science and Technology Co., Ltd (CN) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.